

A Look to the Future for ATHN and You! Hematologist's Perspective

Courtney Thornburg MD, MS
Director, Hemophilia
and Thrombosis Treatment Center

Rady Children's Hospital San Diego Associate Professor UC San Diego



What ATHN Offers the Hematologist

Securing Data-Advancing Knowledge-Transforming Care

- Clinical Manager
 - Tracking and reporting the HTC population
 - Data for research feasibility
- Research Opportunities
 - Participation in national research and surveillance
 - Development of investigator initiated research
 - Support for early career investigators (DREAM award)
- Quality Improvement
 - Training in quality improvement



Clinical Manager

Adaptability for Innovations in Care

- Bleeding Disorders
 - Novel therapeutics
 - beyond factor replacement therapy
 - Focus on transition and transfer of care
 - Focus on the aging population
- Thrombotic Disorders
 - Novel therapeutics
 - beyond warfarin and heparin
 - Focus on anticoagulation safety
 - Focus on prevention of venous thromboembolism



Clinical Manager

Adaptability for Evolving Reporting Requirements

- Local
 - HTC growth
 - Clinical outcomes

- Regional/National (HRSA)
 - Annual reporting
 - Healthy People initiatives
 - Quality Improvement



ATHN's Research and Surveillance Existing portfolio

- ATHN Dataset and Data Quality Counts
- CDC Community Counts
 - Registry
 - Population Profile
 - Mortality Reporting

My Life Our Future



ATHN's National Research and Surveillance Challenges

- Prioritizing research studies at HTC
 - Competing demands
 - ATHN-X; DREAM award projects
 - Industry sponsored
 - Investigator initiated (outside of ATHN)
- Funding
 - Current funding may not align with personnel effort
 - Regulatory
 - Recruitment
 - Specimen collection and processing
 - · Data collection, abstraction, entry and auditing



Investigator Initiated Research with ATHN

Example: ATHN-X

- Development of US PUPs Registry
 - Collaboration: Blood Center of Wisconsin, PedNet, Children's Mercy Hospital, Rady Children's Hospital San Diego and ATHN
 - Initial phase: test feasibility of enrolling PUPs into Registry and collecting all treatment, bleed and inhibitor testing data for the first 50 exposure days
 - Utilizing ATHN's Strengths
 - Clinical Manager and Studies Manager infrastructure
 - Question Library
 - Flexibility with funding flow
 - Existing subcontracts with HTCs



Investigator Initiated Research with ATHN Challenges

- Data to Guide Site Selection (8-10 sites for feasibility phase)
 - Birth rates
 - ATHN data
 - #patients in ATHN Dataset with birth year 2010-2016; need permission from HTCs to get site data
- CRF and Dataset Build
 - Study specific modules using existing questions + customized questions to align with PedNet Registry
 - · \$\$\$\$
 - ATHN priority #X ---> timeline for build and testing



Quality Improvement

Needs Assessment

- Training
 - The Dartmouth Institute Microsystems Academy
 - Time intensive
- Quality Improvement Resources
 - Guidelines and Policies (e.g. Got Transition)
 - Transition Readiness Assessments (e.g. HEMO-Milestones Tool)
 - Educational Tools (e.g. NHF Steps for Living)
- Baseline Data for QI
 - Clinical Manager Query (e.g. #patients 18-25y with annual visit)



Recommendations for ATHN

A Hematologist's Perspective for the Future

- Stay on top of changes in clinical care and reporting requirements
 - Update Clinical Manager
- Understand time commitments for research and surveillance at HTCs
 - Fund accordingly
- Increase accessibility of data to investigators
- Develop novel strategies to reduce costs and time for Database changes
- Continue to promote QI training and sharing of QI resources

